Skip to content

Depression: all studies

Page 831 of 1,036: studies 8,301 to 8,310 of 10,358, newest first. Back to the depression overview

Research

Healthy beneficts of TM in classroom: reduction of anxiety among teachers

INFAD April 9, 2020 Irene Scordo

This research aims at the assessment of healthy effects of the Transcendental Meditation (TM) on anxiety among teachers. Indipendent scientific researches, all over the world, have proved that the category of teachers, among the so called helping professions, is mainly undergoing stress. We must care, and cure, our educational spaces, both promoters and users of education, going directly to the...

DOI: 10.17060/ijodaep.2016.n1.v1.282 (opens in new tab) Full text (opens in new tab) Meditazione trascendentale Benefici scolastici Insegnanti

Will Legalization and Commercialization of Cannabis Use Increase the Incidence and Prevalence of Psychosis?

JAMA Psychiatry April 8, 2020 R. Murray, W. Hall

There is a worldwide trend toward liberalizing cannabis policy and commercializing its sale. Uruguay legalized recreational cannabis in 2013, as did Canada in 2018, as well as 10 US states.1 Other countries have decriminalized the drug. In Holland, cannabis can be bought in designated cafes, and in Portugal, the police refer those who regularly use cannabis for counseling. Psychiatrists have...

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

The International Journal of Neuropsychopharmacology April 7, 2020 Michel Nijs, Ewa Wajs, Leah Aluisio et al. 21 citations

BACKGROUND: Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. METHODS: This is a post-hoc analysis of an open-label, long-term (up to 1 year) study of esketamine in patients with treatment-resistant depression (SUSTAIN 2). During...

Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Psilocybin/Psilocin

Clinical Pharmacology in Drug Development April 6, 2020 Elyes Dahmane, Paul R. Hutson, Jogarao Gobburu 44 citations

Abstract Psilocybin is being developed for treating major depressive disorder. Psilocybin is readily dephosphorylated to psilocin upon absorption. The potential for psilocin proarrhythmic effect was assessed using a concentration‐QTc interval (C‐QTc) analysis from an open‐label single ascending dose study of psilocybin. Psilocybin doses ranged from 0.3 to 0.6 mg/kg. This trial showed a...

DOI: 10.1002/cpdd.796 (opens in new tab) Psilocybin Hallucinogen Pharmacology Qt interval +2

Mindfulness-Based Stress Reduction for Parents Implementing Early Intervention for Autism: An RCT

Pediatrics April 1, 2020 A. Weitlauf, Neill Broderick, J. A. Stainbrook et al.

This study examined whether parents of children with ASD reported better functioning if they received stress-reduction training as part of early behavioral intervention. BACKGROUND AND OBJECTIVES: Systems of care emphasize parent-delivered intervention for children with autism spectrum disorder (ASD). Meanwhile, multiple studies document psychological distress within these parents. This pilot...

Yoga and Mindfulness as a Tool for Influencing Affectivity, Anxiety, Mental Health, and Stress among Healthcare Workers: Results of a Single-Arm Clinical Trial

Journal of Clinical Medicine April 1, 2020 G. L. Torre, Antonino Raffone, Margherita Peruzzo et al.

Mindfulness-based interventions have emerged as unique approaches for addressing a range of clinical and subclinical difficulties such as stress, chronic pain, anxiety, or recurrent depression. Moreover, there is strong evidence about the positive effects of yoga practice on stress management and prevention of burnout among healthcare workers. The aim of this study was to conduct a single-arm...

Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives

Journal of Palliative Medicine April 1, 2020 Yvan Beaussant, Justin J. Sanders, Zachary Sager et al. 39 citations

Background: Recent and preprohibition studies show that patients with serious illness might benefit from psychedelic-assisted therapies for a range of symptoms, physical, psychosocial, and existential. Objective: To explore the potential roles and research priorities of these therapies in patients with serious illness. Design, Setting, and Participants: Qualitative study based on semistructured...

DOI: 10.1089/jpm.2019.0603 (opens in new tab) Anxiety Psychosocial Thematic analysis Distress +4

O USO RITUALISTÍCO E FARMACOLÓGICO DA AYAHUASCA: UMA REVISÃO DE LITERATURA

Revista Interfaces Saúde Humanas e Tecnologia April 1, 2020 Cicero Jerfesson Ferreira Silva, Pedro Walisson Gomes Feitosa, Alyne Oliveira Correia 1 citation

Ayahuasca is a tea with psychoactive properties used by indigenous peoples of South America obtained from the infusion of two plants, Banisteriopsis caapi and Psychotria viridis.From the junction of these plants is obtained a preparation rich in β-carbonyl alkaloids, which promote blockade of Monoaminoxidase (MAO) and considerable concentrations of N, N-dimethyltryptamine (DMT).MAO degrades DMT...

Designer drugs: mechanism of action and adverse effects

Archives of Toxicology April 1, 2020 Dino Luethi, Matthias E. Liechti 258 citations

Abstract Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer...

DOI: 10.1007/s00204-020-02693-7 (opens in new tab) Full text (opens in new tab) Pharmacology Designer drug Mechanism of action Adverse effect +6

One Dose of Psilocybin in Late Adolescence Mitigates Deleterious Effects of Developmental Stress on Cognition and Behavioral Despair in Adult Female Rats

The FASEB Journal April 1, 2020 Meghan Hibicke, Charles D. Nichols 9 citations

Introduction Psilocybin (PSI) has persistent antidepressant efficacy in human trials. We have shown one dose of PSI to significantly decrease depressive‐like behavior in male Wistar‐Kyoto (WKY) rats for at least five weeks without losing efficacy. However, the outcome assay we used to evaluate depressive‐like behavior, the forced swim test (FST), has been criticized for not providing...

DOI: 10.1096/fasebj.2020.34.s1.02912 (opens in new tab) Antidepressant Behavioural despair test Dentate gyrus Cognition +3